We are testing a new treatment called HDP-101 for patients with relapsed or refractory multiple myeloma. The study aims to find a safe dose and evaluate how well it works.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or Refractory Multiple Myeloma (r/r MM) is a type of blood cancer that occurs when plasma cells in the bone marrow become cancerous and either return after treatment (relapsed) or do not respond to treatment (refractory).
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
